English 
Japanese 
November 1, 2021
The CREB-binding protein (CBP)/β-catenin inhibitor E7386, co-created by Eisai and PRISM BioLab, achieved the clinical POC (Proof of Concept)
Eisai Co., Ltd. and PRISM BioLab Co., Ltd. announced today that the CREB-binding protein (CBP) /...
Read More
November 1, 2021
PRISM BioLab raised 100 million yen in Series C funding from Eisai
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More
October 28, 2021
The paper of peptidomimetics is published in ACS Omega
This paper presents the new method to analyze how peptidomimetics scaffold mimic the actual peptide, and PRISM’s scaffold advantage is confirmed.
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
Read More
Visualized and Quantitative Conformational Analysis of Peptidomimetics
ACS omega, 6(40), 26601-26612 (2021)
September 9, 2021
PRISM BioLab raised 1.3 billion yen in Series C funding
PRISM BioLab, the Japan based biotechnology company with proprietary small molecule drug discovery technology ”PepMetics®”, today...
Read More
June 16, 2021
Servier and PRISM BioLab enter drug discovery collaboration for a novel target
PRISM BioLab provides PepMetics® (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against...
Read More
November 4, 2020
PRISM Biolab and Merck enter multi-project drug discovery collaboration
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against...
Read More
June 8, 2020
PRISM Biolab and Boehringer Ingelheim enter multi-project drug discovery collaboration
PRISM Biolab provides The PRISM Library, proprietary library of peptide mimetic small molecules for screening against...
Read More
November 12, 2018
Notice of Our Merger
PRISM Pharma Co.,Ltd. (“Pharma”) and its wholly owned subsidiary, PRISM BioLab Co.,Ltd.(“BioLab”), have merged as of...
Read More